1. Home
  2. EMBC vs RNA Comparison

EMBC vs RNA Comparison

Compare EMBC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$5.15

Market Cap

199.9M

Sector

Health Care

ML Signal

HOLD

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

HOLD

Current Price

$12.39

Market Cap

222.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMBC
RNA
Founded
1924
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.9M
222.5M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
EMBC
RNA
Price
$5.15
$12.39
Analyst Decision
Buy
Buy
Analyst Count
2
20
Target Price
$18.50
$69.26
AVG Volume (30 Days)
1.6M
106.6K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
6.88%
N/A
EPS Growth
20.90
N/A
EPS
1.03
N/A
Revenue
N/A
N/A
Revenue This Year
$1.17
$88.12
Revenue Next Year
N/A
$18.11
P/E Ratio
$4.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.77
$11.13
52 Week High
$15.55
$73.06

Technical Indicators

Market Signals
Indicator
EMBC
RNA
Relative Strength Index (RSI) 74.48 53.98
Support Level $3.01 $11.95
Resistance Level $9.38 $14.05
Average True Range (ATR) 0.31 0.34
MACD 0.17 0.12
Stochastic Oscillator 96.51 87.08

Price Performance

Historical Comparison
EMBC
RNA

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: